Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tenofovir disoproxil

- PMLiVE

Gilead Sciences supports Kigali Declaration for neglected tropical diseases

1.7 billion people around the world are affected by tropical diseases, which are prevalent in tropical areas and mostly affect impoverished communities

- PMLiVE

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

- PMLiVE

Gilead signs $300m deal with Dragonfly to advance immunotherapies

The partnership will make use of Dragonfly’s oncology and inflammatory disease research capabilities

- PMLiVE

BMS Foundation announces Robert A Winn Diversity in Clinical Trials Award Program

The $100m initiative was started in 2020 to increase diversity in clinical trials

- PMLiVE

Janssen submits marketing authorisation to EMA for teclistamab

The drug has been developed to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment

The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma

- PMLiVE

AstraZeneca’s Saphnelo to be approved in Europe for lupus

The EMA is set to approve the first new treatment for systemic lupus erythematosus in Europe in more than a decade

- PMLiVE

Gilead’s Trodelvy approved for triple-negative breast cancer in Europe

European patients with metastatic triple-negative breast cancer can now receive the antibody-drug conjugate as second-line monotherapy

Biogen Idec building

Biogen’s Aduhelm unlikely to get approval in Europe

In another setback for the controversial Alzheimer’s disease antibody, the EMA’s review committee has voted against recommending the treatment

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail approved in Europe

Ronapreve (REGEN-COV in the US) has been approved for non-hospitalised, at-risk patients and for prevention of COVID-19

- PMLiVE

Eisai/Biogen present more data on antibody for Alzheimer’s disease

Phase 2 data shows lecanemab offers a consistent ‘robust’ effect against Alzheimer’s disease, while the phase 3 programme will test plasma biomarkers to identify preclinical disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links